NCT03529110: A reported trial by Daiichi Sankyo
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03529110 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 9, 2018 |
| Completion date | May 21, 2021 |
| Required reporting date | May 21, 2022, midnight |
| Actual reporting date | March 7, 2022 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |